Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its position in Twist Bioscience Co. (NASDAQ:TWST) by 9.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,100 shares of the company’s stock after purchasing an additional 1,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Twist Bioscience were worth $789,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TWST. SG Americas Securities LLC purchased a new stake in shares of Twist Bioscience in the 1st quarter valued at approximately $893,000. GAMMA Investing LLC grew its position in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the period. Pallas Capital Advisors LLC purchased a new position in Twist Bioscience in the first quarter worth approximately $201,000. Farther Finance Advisors LLC increased its stake in Twist Bioscience by 18.5% during the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company’s stock worth $251,000 after acquiring an additional 1,006 shares during the last quarter. Finally, NBC Securities Inc. purchased a new stake in Twist Bioscience in the first quarter valued at $337,000.

Twist Bioscience Price Performance

Shares of TWST opened at $33.52 on Monday. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -9.92 and a beta of 2.38. The firm’s fifty day simple moving average is $34.05 and its 200-day simple moving average is $41.52. Twist Bioscience Co. has a twelve month low of $27.12 and a twelve month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 1,101 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $41,452.65. Following the completion of the sale, the senior vice president now owns 129,380 shares in the company, valued at $4,871,157. This represents a 0.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 936 shares of the firm’s stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $27,846.00. Following the transaction, the chief financial officer now directly owns 106,018 shares in the company, valued at $3,154,035.50. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,920 shares of company stock valued at $814,067 over the last ninety days. Insiders own 3.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Guggenheim reaffirmed a “buy” rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. Finally, Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.